Clinical Trial Update: Quelling of Excitotoxicity in Acute Stroke With Ketamine [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for ketamine aimed at reducing excitotoxicity in acute ischemic stroke, currently in Phase 2 and Phase 3 stages, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Lower Merion Neurology Research Foundation | Conditions: Acute Ischemic Stroke | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING